Moxifloxacin for Refractory, Recurrent, Multi-Drug Resistant Pulmonary Tuberculosis: A Systematic Review

OBJECTIVE To assess the effectiveness and security of moxifloxacin for refractory, recurrent, multi-drug resistant pulmonary tuberculosis. METHODS To search he Medline(1950－2009), FJIS(1995－2008), CNKI(1994－2008), CBMdisc(1977－2008) , WHO EML to collect randomized controlled trails (RCTs) which moxifloxacin was uesd for refractory, recurrent, multi-drug resistant pulmonary tuberculosis. RESULTS The data included 7 RCTs was analyzed by using the Cochrane Collaboration’s RevMan 4.2.10 software. Compared with control group, moxifloxacin was more effective in sputum negative conversion rate RR=1.11, 95%CI(1.03, 1.19) and clinical efficacy rateRR=1.14, 95%CI(1.04, 1.25). CONCLUSION Moxifloxacin is useful for sputum negative conversion in patients with refractory, recurrent, multi-drug resistant pulmonary tuberculosis.